ErVimmune-preview

Ervimmune

ErVimmune

Private

LyonHealthcare & Life Scienceshttps://ervimmune.com

Last Round

Series A

Jan 21, 2026

Total Funding Raised

$7.3M

Company Overview

ErVimmune is a biotechnology company developing therapeutic vaccines and cell therapies to treat cancers that do not respond to current immunotherapies.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Government Contracts, Services & Consulting

AI Layer

Non-AI

Keywords

human endogenous retrovirusesHERVstherapeutic vaccinescancer vaccinescold tumorsimmuno-oncologyIOT-cell therapyantigen discoveryHERV antigensoff-the-shelf vaccinetriple-negative breast cancerTNBCovarian cancerpreclinical biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ErVimmune Comps

Public and private peers based on sector, stage, and business model.

Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

ErVimmune Funding Rounds

Historical fundraising activity

Round	Date	Amount Raised	Valuation	Investors	Sources
Series A	Jan 21, 2026
Grant	Nov 1, 2023
Seed	Jan 9, 2023

View all Funding Rounds

Key People

Founding team and executive leadership

Nathalie Donne

Chief Executive Officer

Executive Team

ErVimmune Investors

Notable investors and investment history

Investor	Rounds
SPRIM Global Investments	Series A
EIC Accelerator	Grant
SPRIM Global Investments	Series A
Bpifrance	Seed
Seventure Partners	Seed, Series A

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

Jan 21, 2026
$20M raised in Series A financing.
Jan 21, 2026
Eric Halioua appointed executive chairman of the board.

View all signals

ErVimmune Filings

SEC and related filings with document metadata.

Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

ErVimmune Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about ErVimmune's valuation, stock price, and market status.

Firmographic Details

HeadquartersLyon

Employee Range17

Year Founded2019

Last FundingJan 21, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.